HER2 ADC Competitive Intelligence

What this research found

Enhertu (trastuzumab deruxtecan) leads the HER2 antibody-drug conjugate field, and this competitive intelligence report asks how durable that lead is as the basis for a long position in Daiichi Sankyo. It maps 521 registered HER2 conjugate trials, compares payload chemistry against rival drugs, and quantifies the interstitial lung disease signal that is the platform's main liability. The 22-page report finds a measurable chemical basis for Enhertu's bystander-killing advantage sitting alongside a 7.5-fold higher lung toxicity rate than Kadcyla.

• A sweep of 756 registered studies identified 521 HER2 antibody-drug conjugate trials across 199 sponsors, of which 59 are run by Daiichi Sankyo or AstraZeneca. In DESTINY-Breast03, Enhertu reached a median overall survival of 52.6 months, roughly 10 months longer than Kadcyla.
• The bystander effect has a physicochemical basis. The DXd payload weighs 516.0 daltons, 201.9 daltons less than MMAE, and has a polar surface area of 86.3 square angstroms, 63.7 lower — both properties that favour diffusion across cell membranes into neighbouring tumour cells.
• The same properties plausibly drive the toxicity. Enhertu shows 10.5% all-grade interstitial lung disease in trials against 1.4% for Kadcyla, a 7.5-fold difference, and 0.3% for Herceptin, a 35-fold difference. Spontaneous reporting echoes it: 111.34 lung-disease reports per 1,000 adverse events against 13.60 for Kadcyla.
• Three mechanisms explain the gap. DXd is a topoisomerase I inhibitor, so it affects rapidly dividing cells including the type II pneumocytes involved in lung repair; Enhertu carries roughly eight payload molecules per antibody against about 3.5 for Kadcyla; and its GGFG linker is engineered for efficient cleavage.
• The HER2-low indication opened up by DESTINY-Breast04 expands the addressable population by roughly 50%. The bear case rests on the lung toxicity, competition from Chinese developers such as RemeGen, biosimilar trastuzumab pricing pressure and manufacturing scale-up risk.

How it was done

ClinicalTrials.gov was queried for HER2 antibody-drug conjugate studies and the results tabulated by sponsor and development stage. Payload chemistry came from ChEMBL, comparing molecular weight, lipophilicity and polar surface area for the topoisomerase I inhibitors DXd and SN-38 against the microtubule inhibitors DM1 and MMAE, which produced a structural account of the bystander effect. Safety was benchmarked two ways: all-grade interstitial lung disease rates from the DESTINY-Breast and EMILIA trials, and lung-disease reports per 1,000 adverse events from the FDA's spontaneous reporting system for Enhertu, Kadcyla and Herceptin. Open Targets was used to rank ERBB2 disease associations across 16 cancer indications, and the analysis was written up as a 22-page report with a bibliography of 20 peer-reviewed references.

Data sources

• ClinicalTrials.gov — 756 studies queried, 521 HER2 antibody-drug conjugate trials across 199 sponsors
• Open Targets Platform — ERBB2 disease associations across 16 cancer indications
• ChEMBL — physicochemical and bioactivity data for the DXd, DM1, MMAE and SN-38 payloads
• FDA Adverse Event Reporting System — 8,380 Enhertu reports, 8,162 for Kadcyla and 65,400 for Herceptin
• Published trials DESTINY-Breast03, DESTINY-Breast04 and EMILIA, plus FDA-approved product labels

Figures from this analysis